Poxviridae

Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Date of authorisation: 06/01/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Family, Agency, Human body, INN, Survival, Infection, Survival rate, Virus, ATC, Capsule, International, Mortality, Headache, Nausea, Language, Mouth, Human, Vaccination, Medicine, Poxviridae, Animal, European Medicines Agency, Viral, Orthopoxvirus, Select, Patient, Diagnosis, Safety, Anatomy, IIA, Vaccine

Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Date of authorisation: 06/01/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Date of authorisation: 06/01/2022, Revision: 3, Status: Authorised

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation

Retrieved on: 
Wednesday, September 20, 2023
GMP, LSE, Official List, Poxviridae, Oxford, QC, European Union (Withdrawal) Act 2018, London Stock Exchange, AGM, Equity, Immunotherapy, OXB, Lentivirus, CDMO, EBITDA, Acquisition, VWAP, Financial Conduct Authority, Vivisection, Potyvirus, ABL, Depreciation, Growth, Virus, Companies Act 2006, Completion, MVA, Vaccine, Fine chemical, Retail, Bookkeeping, Oxford Biomedica, EU, Vaccinia, European, Adenoviridae

596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Key Points: 
  • 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
  • This Proposed Transaction would form part of Oxford Biomedica’s transformation to be a world-leading quality focused and innovation-led CDMO in the cell and gene therapy field.
  • As at 31 December 2022, ABL Europe had earnings before interest tax and depreciation (EBITDA) of c.€(1.7)m and gross assets of c.€23.6m.
  • Currently, the Proposed Transaction would constitute a Class 2 transaction for the purposes of the UK Financial Conduct Authority’s Listing Rules.

mergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox

Retrieved on: 
Tuesday, October 18, 2022
Monkeypox virus, Smallpox, Zoonosis, Pox, Disease, Fluid mechanics, Virus, Infection, Vaccine, Poxviridae, GMP, Laboratory, Society, Survivor, Severe acute respiratory syndrome coronavirus 2, Intelligence, Monkeypox, Entrepreneurship, Gastroenterology, Severe cognitive impairment, Scar, Construct, World, Kinetics, CEO, World Health Organization, Vaccination, DNA, Peptide, Death, MedRxiv, DG, HLA

The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.

Key Points: 
  • The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.
  • The fact that the vaccine constructs pathogen peptides come from the eclipse phase of viral replication plays a key role in infection kinetics.
  • Phillip Williams, Chief Scientific Officer at Emergex commented: Were very proud to have synthesized this smallpox and monkeypox vaccine so quickly using intelligence and resources to target highly conserved sequences shared by both viruses.
  • With a fatality rate of >30% in unvaccinated people, there are concerns that smallpox could pose a future biosecurity threat.

Global Gene Therapy Market Analysis Report 2022: M&As Rampant in the Gene Therapy Space - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Genetics, CAR, Vaccinia, Growth, Investment, Cancer, Incidence, Prevalence, Research, Government, Gene, DNA, COVID-19, Lists of diseases, Conditional sentence, Biotechnology, RNA, Safety, Awareness, CAGR, Virus, Herpes simplex virus, Retrovirus, AAV, Fine chemical, Pharmaceutical industry, Vaccine, Pet, Lentivirus, Poxviridae

The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Gene Therapy estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$2.7 Billion by 2026, growing at a CAGR of 19.5% over the analysis period.
  • Non-viral vectors are perceived as safer substitute to viral vectors, and playing an important role in redirecting pharmaceutical industries and clinicians towards gene therapy.
  • In Europe, rising funding for cell and gene therapy programs in countries such as the UK is expected to steer the gene therapy market in the region.

DGAP-News: Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Retrieved on: 
Wednesday, August 10, 2022
Survival, Poxviridae, Research, Molluscum contagiosum, Fever, Patient, Family, Hepatitis C, Influenza, Hepatitis B virus, US, Monkeypox virus, Animal, Degenerative disease, Smallpox, Dengue fever, Travel, Technology, Fear, Kidney, DNA, Safety, EKC, Ulcer, DNA virus, Remdesivir, Monkeypox, Smallpox vaccine, Virus, Simplex, HBV, Pox, SIGA Technologies, US FDA, Rash, COVID-19, Bioterrorism, Drug development, Vaccination, Disease, HIV, HCV, Time, Keratitis, Advertising, FDA, Bird, VZV, NYSE, Population, Shingles, IND, Company, Lymph, Eye, NASDAQ, Human, Consultant, Gilead, Pharmaceutical industry, Vaccine, Rabies, West Nile virus, Central Africa

However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.

Key Points: 
  • However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.
  • It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection.
  • Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants.
  • During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections.

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

Retrieved on: 
Wednesday, June 22, 2022
Emergent BioSolutions, Biomedical Advanced Research and Development Authority, Monkeypox virus, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, United Kingdom, U.S. Securities and Exchange Commission, Documentation, CDC, Human services, GLOBE, Cowpox, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, FDA, COVID-19, Poxviridae, Government, BARDA, IV, Xi, Vaccinia, Tonix Pharmaceuticals, Risk, Vaccine, Human, Research, Smallpox vaccine, Ix, Development, EMA, Assistant, Pharmaceutical industry, EU

The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.

Key Points: 
  • The chat will be hosted by Alliance Global Partners and will also include representatives from Emergent Biosolutions and Tonix Pharmaceuticals.
  • The FDA has not approved TPOXX for monkeypox in the US.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Retrieved on: 
Wednesday, June 22, 2022
Hepatitis, Population, Security (finance), MVA, Old Road Campus, University of Oxford, Infection, Disease, University, Poxviridae, GLOBE, Poster, Annual report, CHB, ChAdOx1, Oxford University Innovation, Hepatology, Private Securities Litigation Reform Act, Antigen, Degenerative disease, DNA, Immune system, NASDAQ, SEC, Medical school, COVID-19, Knowledge, OXFORD, Nivolumab, OUI, Immune tolerance, Patient, Nuffield Department of Population Health, U.S. Securities and Exchange Commission, Immunotherapy, EASL, AstraZeneca, Chinese University of Hong Kong, Safety, Vaccine, Liver, Company, Cancer, Medical research, Genotype, Faculty, Autoimmunity, HBV, Pharmaceutical industry, Vaccitech, Medicine, HBsAg

OXFORD, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 study (NCT04778904), which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.

Key Points: 
  • Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
  • These three patients had 0.7, 0.7 and 1.4 log10 declines two months after the last dose of VTP-300.
  • These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300.

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Monday, June 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV).

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Monday, June 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, OXFORD, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom

Retrieved on: 
Wednesday, June 30, 2021
Chordopoxvirinae, Poxviruses, Medical specialties, Virology, Viral diseases, Monkeypox, Smallpox, Tecovirimat, Poxviridae, Pox, Infection, Orthopoxvirus

TPOXX, which is approved in the United States for the treatment of smallpox, was delivered to Liverpool for compassionate treatment for a patient confirmed to be infected with monkeypox.

Key Points: 
  • TPOXX, which is approved in the United States for the treatment of smallpox, was delivered to Liverpool for compassionate treatment for a patient confirmed to be infected with monkeypox.
  • Monkeypox is a contagious disease caused by infection with monkeypox virus, a virus closely related to variola virus, which causes smallpox.
  • Monkeypox is characterized by severe flu-like symptoms and a rash of pus-filled pocks that may cover the whole body.
  • On July 2018, the U.S. Food and Drug Administration (FDA) approved the oral formulation of TPOXX (tecovirimat) for the treatment of smallpox.